Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors : meta-regression analysis of 78 randomized controlled trials with 20,053 patients.

摘要: Ability to predict which patients might benefit more of therapy facilitate personalization treatment. The aim this study was obtain information about clinical characteristics the HbA1c response DPP-4 inhibitors. We conducted an electronic search without restriction for randomized controlled trials (RCTs) involving inhibitors (vildagliptin, sitagliptin, saxagliptin, linagliptin, and alogliptin). RCTs were included if they lasted at least 12 weeks, reported effect on level, number in any arm >30. did a meta-regression analysis. Seventy-eight articles eligible, with 79 arms 20,503 patients. For all arms, decrease −0.74 % (95 CI −0.80 −0.67 %), considerable heterogeneity (I2 = 97 %, P < 0.0001): greatest seen 52 weeks (8 3,338 patients, −0.88 95 −1.10 −0.66 %). In univariate analysis, baseline explained 22 variance treatment, while fasting glucose type inhibitor additional 19 respectively; age, duration previous therapy, statistical analysis influence. multivariate model, HbA1c, glucose, 61 total variance. can be modulated mainly by levels: greater absolute reduction is higher lower level.